Janssen Enters Into Worldwide Collaboration With Theravance Biopharma For Oral, Pan-JAK Inhibitor Drug Candidate For The Treatment Of Inflammatory Bowel Disease

February 7, 2018

Responsive image

HORSHAM, Pa., Feb. 7, 2018 /PRNewswire/ — The Janssen Pharmaceutical Companies of Johnson & Johnson announced today their entry into a worldwide collaboration with an affiliate of Theravance Biopharma, Inc. to develop TD-1473, a first-in-class oral, gastrointestinal (GI) restricted…

Category: Precious Metals